166 related articles for article (PubMed ID: 10357402)
1. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Partyka S; Dumas P; Ajani J
Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Chiou TJ; Tung SL; Hsieh RK; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Jpn J Clin Oncol; 1998 May; 28(5):318-22. PubMed ID: 9703859
[TBL] [Abstract][Full Text] [Related]
3. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
8. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
Bajetta E; Di Bartolomeo M; Carnaghi C; Buzzoni R; Mariani L; Gebbia V; Comella G; Pinotti G; Ianniello G; Schieppati G; Bochicchio AM; Maiorino L
Br J Cancer; 1998 Apr; 77(7):1149-54. PubMed ID: 9569054
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
[TBL] [Abstract][Full Text] [Related]
12. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
13. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.
Van Cutsem E; Filez L; Dewyspelaere J; Penninckx F; Janssens J
Anticancer Res; 1995; 15(3):1079-80. PubMed ID: 7645929
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
15. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
[TBL] [Abstract][Full Text] [Related]
17. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.
Hejna M; Kornek GV; Raderer M; Marosi L; Schneeweiss B; Greul R; Weinländer G; Valencak J; Huber H; Scheithauer W
Oncology; 1998; 55(6):538-42. PubMed ID: 9778620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
